The present invention is drawn to new oral live canine parainfluenza virus vaccines and related multivalent vaccines. Methods of using the vaccine alone or in combination with one or more other protective immunogens in multivalent vaccines are also provided.

The present invention is drawn to new oral live canine parainfluenza virus vaccines and related multivalent vaccines. Methods of using the vaccine alone or in combination with one or more other protective immunogens in multivalent vaccines are also provided.

The present invention relates to use of probiotic compositions and/or histamine degrading enzymes for the control of histamine in a farm production animal, companion animal, aquaculture, or a human, to reduce or eliminate the incidence of necrotizing enterocolitis and/or related inflammatory conditions in the gastrointestinal tract or skin, and behavioral conditions. The invention also relates to the probiotic compositions and/or histamine degrading enzymes.

Provided are novel imidazopyrazine derivatives having the general formula (I), wherein R.sup.1 to R.sup.11 are as described herein

##STR00001##

and pharmaceutically acceptable salts thereof.

Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and related diseases.

Provided are novel imidazopyrazine derivatives having the general formula (I), wherein R.sup.1 to R.sup.11 are as described herein

##STR00001##

and pharmaceutically acceptable salts thereof.

Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and related diseases.

The present disclosure provides compositions comprising an isolated polysaccharide comprising β-1,4 linked galactosamine and glucosamine monomers, wherein the amino groups of each of the galactosamine and glucosamine are partially substituted with acetate. The disclosure further provides vaccine, methods of use, and methods of producing the isolated polysaccharide.

The present disclosure provides compositions comprising an isolated polysaccharide comprising β-1,4 linked galactosamine and glucosamine monomers, wherein the amino groups of each of the galactosamine and glucosamine are partially substituted with acetate. The disclosure further provides vaccine, methods of use, and methods of producing the isolated polysaccharide.

The present invention provides compositions of CD180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.

The present disclosure provides fused 1,4-oxazepines and related analogs represented by Formula (I) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R.sup.1, R.sup.2a, R.sup.2b, R.sup.3a, R.sup.3b, R.sup.4, R.sup.5, A, and Y are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a condition or disorder responsive to inhibition of BET bromodomains such as cancer. ##STR00001##

Provided herein are compounds, derivatives thereof, composition comprising one or more of said compounds and derivatives prevention and/or treatment of microbial infections and/or related diseases or conditions. The present compounds and/or derivatives thereof can be represented by Formula (I):

##STR00001##

In one embodiment, said microbial infections are bacterial infections. More specifically, said bacterial infections are staphylococcal infections.